Senores Pharma Q2 FY27 Revenue Up 25% to ₹192 Cr; PAT Up 22% to ₹37 Cr
Senores Pharma reported Q2 FY27 consolidated revenue of ₹192 Cr (+25% YoY) and PAT of ₹37 Cr (+22% YoY). H1 FY27 revenue was ₹373 Cr (+30% YoY) with PAT at ₹67 Cr (+31% YoY). The company expects 30-40% revenue and 50-60% PAT growth in FY27.
The announcement details significant financial growth, expansion of product portfolio, and a strong forward-looking guidance, which are material events for investors and the market.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT for both the quarter and half-year, exceeding previous performance and providing a positive outlook for the fiscal year.
Senores Pharmaceuticals Limited announced its unaudited consolidated financial results for the quarter and half year ended September 30, 2026. The company reported a robust financial and operational performance, achieving its highest-ever quarterly revenue and EBITDA in Q2 FY27.
For the second quarter of FY27, consolidated revenue stood at ₹192 crores, marking a 25% year-on-year increase. EBITDA grew by 38% year-on-year to ₹58 crores, with a margin expansion of approximately 290 basis points. Profit After Tax (PAT) for the quarter rose by 22% year-on-year to ₹37 crores.
In the first half of FY27, consolidated revenue reached ₹373 crores, up 30% year-on-year. EBITDA saw a significant increase of 58% year-on-year to ₹111 crores, with a margin expansion of approximately 530 basis points. PAT for the half-year grew by 31% year-on-year to ₹67 crores.
The company's Regulated Markets business showed strong momentum, with the ANDA portfolio nearly doubling to 64 as of September 2026, from 34 in September 2025. Of these, 23 ANDAs have been commercialized, with 41 planned launches over the next 18-24 months. The Emerging Markets business also continued its steady growth, with revenues increasing by 21% and 25% year-on-year in Q2 and H1 FY27, respectively.
Cash from Operations improved to ₹38 crores in H1 FY27. The company noted that initial setup and operating costs for Zoraya and Amerisyn temporarily impacted profitability, but their scale-up from FY28 onwards is expected to drive operating leverage and improve margins.
Senores Pharmaceuticals Limited is on track to deliver 30-40% revenue growth and 50-60% PAT growth in FY27, with an anticipated annual growth of 20-25% over the next two years. This outlook is supported by a robust product pipeline, expanded manufacturing capabilities, and strong commercial launch visibility.
What to do with a filing like this
Senores Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Senores Pharmaceuticals Limited. Read the original for the full detail.